Healthcare entity
FDA is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 14-day span, the pace is roughly 1 story per week. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 14-day span, the pace is roughly 1 story per week. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window. The 6 average consequence score is above the beat benchmark of 5.8 in the same window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Healthcare stories mentioning Psilocybin across the period from February 21, 2026 to March 6, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 239 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Psilocybin. Shared-story counts are live from our verified record — not editorial picks.
Valuation Period
Expected timeframe for determining the fair market value of the equity investment.
Palliative Care Findings
New research confirms high efficacy rates for mitigating end-of-life distress in oncology settings.
Option Exercised
PsyLabs officially triggers the put option, requiring an equity investment from PBM.
Put Option Established
Psyence BioMed and PsyLabs enter into a strategic put option agreement.
SAP Expansion
Canada formally expands the Special Access Program to include restricted psychedelic substances.
Canadian Exemptions
Health Canada grants the first legal exemptions for psilocybin use to four terminally ill patients.
FDA Breakthrough Status
FDA grants Breakthrough Therapy designation to psilocybin for treatment-resistant depression.
Clinical research into psilocybin-assisted therapy is demonstrating significant potential in mitigating existential distress and depression among terminally ill patients. These findings are driving a re-evaluation of palliative care protocols and accelerating the push for expanded regulatory access to psychedelic-based treatments.
Source: ottawasun.com · edmontonsun.com
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.
Source: CBJ (ca) · manilatimes.net
Psilocybin is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
